CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR-T 细胞治疗与外周实体瘤重建性肿瘤外科手术：叙述性综述

CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.

多重装甲同种异体 MUC1 CAR-T 细胞增强三阴性乳腺癌的疗效与安全性

Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer.

通过 TRAIL 受体 2 选择性靶向髓源性抑制细胞以增强 CAR-T 细胞治疗乳腺癌的疗效

Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast

我们的研究结果表明，共表达 TR2.4-1BB 受体的 CAR-T 细胞对含有免疫抑制和促肿瘤 MDSC 的乳腺肿瘤表现出更强的抗肿瘤潜力，从而导致 TME 重塑并改善肿瘤部位的 T 细胞增殖。

CAR-T 细胞治疗乳腺癌的进展与挑战：从分子设计到临床应用

Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.

乳腺癌管理中的 CAR-T 细胞治疗：拓展视野并克服血液系统肿瘤之外的挑战

CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.

三阴性乳腺癌进展中肿瘤干细胞对 MUC1-C 的依赖性

Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression.

MUC1 CAR-T 细胞治疗乳腺癌：I 期临床试验（Minerva Biotechnologies）

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

这是一项 I 期注册临床试验，评估 CAR-T 细胞治疗乳腺癌的安全性、可行性及初步疗效。当前状态：招募中。计划入组 69 例。试验地点：美国 · 杜阿尔特（共 1 个中心）。登记号：NCT04020575。

靶向黏蛋白-1 的 CAR-T 细胞在免疫健全宿主中有效且安全地控制实体瘤

Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.

靶向 ErbB 和 MUC1 的口腔鳞状细胞癌 CAR-T 细胞免疫治疗

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma.

乳腺癌治疗中 CAR-T 细胞共刺激结构域的体外比较

An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.